Al-Omar Hussain Abdulrahman, Attuwaijri Abdulaziz Abdulhadi, Aljuffali Ibrahim Abdulrahman
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Advisor for the Saudi Health Technology Assessment Center, Ministry of Health, Riyadh, Saudi Arabia.
Saudi Pharm J. 2020 Jun;28(6):662-668. doi: 10.1016/j.jsps.2020.04.006. Epub 2020 Apr 23.
Saudi Arabia is undergoing a massive healthcare transformation to fulfill its new, national "Vision 2030." To align with this objective, Saudi Arabia is establishing a new, independent and evidence-based health technology assessment (HTA) entity to help it maximize health gains through efficient use of resources. This study was designed to ascertain how pharmaceutical companies perceive the creation of such a national HTA entity in Saudi Arabia; what they think about it and expect from it. To achieve the study's aim, we held a workshop in Riyadh, Saudi Arabia, lasting four and a half hours and hosted by the Saudi Ministry of Health (MOH). We invited 16 market access directors and managers from different multinational pharmaceutical companies to discuss the establishment of a national HTA entity. The findings from the workshop were structured around three axes: vision and remit; HTA method; and implementation and practical considerations. Overall, the pharmaceutical company participants were positive about HTA's value for the Saudi healthcare system and expressed willingness to adapt to meet its future requirements.
沙特阿拉伯正在进行大规模的医疗保健转型，以实现其新的国家“2030年愿景”。为了与这一目标保持一致，沙特阿拉伯正在建立一个新的、独立的且基于证据的卫生技术评估（HTA）实体，以帮助其通过有效利用资源实现最大程度的健康收益。本研究旨在确定制药公司如何看待沙特阿拉伯设立这样一个国家HTA实体；他们对此有何看法以及有何期望。为实现该研究目标，我们在沙特阿拉伯利雅得举办了一场由沙特卫生部（MOH）主持的为期四个半小时的研讨会。我们邀请了来自不同跨国制药公司的16位市场准入总监和经理，讨论国家HTA实体的设立。研讨会的结果围绕三个轴展开：愿景和职责范围；HTA方法；以及实施和实际考量。总体而言，制药公司参与者对HTA对沙特医疗保健系统的价值持积极态度，并表示愿意做出调整以满足其未来要求。
